tirzepatide
News •
-
What is tirzepatide?
Tirzepatide is a synthetic antidiabetic medication for treating type 2 diabetes. It was approved by the FDA in 2022 under the name Mounjaro. Tirzepatide is the first in a class of drugs known as dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists.
As incretin hormones, GLP-1 and GIP stimulate pancreatic beta cells to release insulin. Tirzepatide mimics incretins by binding to GLP-1 and GIP receptors, improving insulin secretion and sensitivity, and decreasing glucagon secretion, which helps to regulate blood glucose levels. Tirzepatide can cause gastrointestinal side effects such as nausea and vomiting.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is tirzepatide used to treat?
Tirzepatide is a synthetic antidiabetic drug used to treat type 2 diabetes. Marketed under the name Mounjaro, it was approved by the FDA in 2022 and is administered via injection once a week.
Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, sometimes called a twincretin, that mimics incretin hormones to stimulate insulin release in the pancreas. In type 2 diabetes, cells become resistant to insulin, leading to high blood glucose. Tirzepatide improves insulin secretion and sensitivity, decreases glucagon secretion, delays gastric emptying, increases satiety, and reduces food intake, resulting in lower blood glucose levels and weight loss.
Common side effects include gastrointestinal issues like abdominal pain, nausea, and diarrhea.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How does tirzepatide work in the body?
Tirzepatide is a synthetic drug for treating type 2 diabetes. It belongs to a class of medications called dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists, and is administered via injection under the skin once per week.
Tirzepatide mimics the functions of naturally occurring incretins by binding to and activating GLP-1 and GIP receptors. Activation of GLP-1 receptors improves glucose-mediated insulin secretion and reduces glucagon secretion. Activation of GIP receptors increases insulin sensitivity and secretion, which helps to strengthen the mechanisms that regulate blood glucose levels. Tirzepatide can also delay gastric emptying and increase satiety, leading to reduced food intake and weight loss.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What type of medicine is tirzepatide?
Tirzepatide is a synthetic antidiabetic medication for treating type 2 diabetes. It belongs to the drug class of dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists, and is sometimes called a twincretin because it contains analogs of GLP-1 and GIP, mimicking the effects of naturally occurring incretins.
Tirzepatide improves insulin secretion and decreases glucagon secretion by activating GLP-1 receptors. It increases insulin sensitivity and secretion by activating GIP receptors, which helps to regulate blood glucose levels. Tirzepatide can also delay gastric emptying and increase satiety, which reduces food intake and leads to weight loss.
Common side effects include gastrointestinal issues like abdominal pain, nausea, and diarrhea. It was approved by the FDA in 2022 under the name Mounjaro and is injected under the skin weekly.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What are some possible side effects of tirzepatide?
Tirzepatide, used to treat type 2 diabetes, can cause side effects, most of which are gastrointestinal, including abdominal pain, constipation, decreased appetite, diarrhea, nausea, and vomiting. Less common side effects are heartburn, accelerated heart rate, fever, facial swelling, and itchy or red skin. Tirzepatide is not recommended for people taking GLP-1 agonists or those at risk for thyroid cancer or multiple endocrine neoplasia syndrome type 2.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How does tirzepatide compare to other diabetes and weight loss medications?
Tirzepatide is a synthetic antidiabetic drug used to treat type 2 diabetes. It belongs to a class of drugs known as dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists.
Tirzepatide mimics the effects of incretin hormones, improving glucose-mediated insulin secretion, decreasing glucagon secretion, augmenting insulin sensitivity, and increasing satiety, which helps to regulate blood glucose levels, reduce food intake, and promote weight loss.
However, individuals already taking GLP-1 agonists should not use tirzepatide.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
tirzepatide, synthetic antidiabetic drug used in the treatment of type 2 diabetes. Tirzepatide is the first drug in a class of agents known as dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists. Because both GLP-1 and GIP are so-called incretin hormones (substances produced in the body that stimulate beta cells in the pancreas to release insulin), the drug is sometimes also referred to as a “twincretin.”
Tirzepatide was approved for the treatment of type 2 diabetes by the U.S. Food and Drug Administration (FDA) in 2022, under the trade name Mounjaro. It is administered via injection under the skin once per week.
Mechanism of action
Insulin is a hormone that regulates the level of glucose (sugar) in the blood. It is secreted by beta cells in the islets of Langerhans in the pancreas when blood glucose levels increase, such as after a meal. When blood glucose levels decrease, insulin secretion stops, and glucagon, another hormone produced by cells in the islets of Langerhans, stimulates the liver to release glucose into the blood.
" height="20" alt="HEW Logo">
In type 2 diabetes, however, cells and tissues become resistant to insulin or the body is unable to produce sufficient amounts of insulin, resulting in hyperglycemia (abnormally high blood glucose). The condition is also associated with reduced effects of the GLP-1 and GIP incretin hormones. Because the incretins play a key role in augmenting insulin secretion following nutrient intake, their reduced activity has a further impact on blood glucose dysregulation. Type 2 diabetes is strongly associated with obesity, and, thus, blood glucose levels often can be controlled through diet and exercise. Nonetheless, some persons with the condition require more-intensive treatment with medication.
Tirzepatide contains two polypeptides, one of which is an analog of GLP-1 and the other an analog of GIP. These analogs bind to and activate their corresponding receptors, essentially mimicking the effects of the naturally occurring incretins. In particular, tirzepatide activation of GLP-1 receptors improves glucose-mediated insulin secretion and decreases secretion of glucagon. Tirzepatide activation of GIP receptors augments insulin sensitivity and secretion and thereby helps reinforce the mechanisms regulating blood glucose levels. Owing to the drug’s additional effects, such as delayed gastric emptying and increased satiety after nutrient consumption, its use is further associated with reduced food intake and weight loss.
Side effects
The use of tirzepatide is associated primarily with gastrointestinal side effects, such as abdominal pain, constipation, decreased appetite, diarrhea, nausea, and vomiting. Less common side effects include heartburn, accelerated heart rate, fever, swelling of the face, and itchy or red skin. The use of tirzepatide is limited in certain individuals, owing to contraindications. Such individuals include those already taking GLP-1 agonists (e.g., liraglutide or semaglutide) and persons who are at risk for certain thyroid-related cancers (e.g., medullary thyroid carcinoma) or who have a history of multiple endocrine neoplasia syndrome type 2, since tirzepatide could theoretically increase the chances of developing such tumors in persons with preexisting risk factors.